Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
Analyst Ratings
This is a summary of recent recommendations and price targets for Dermata Therapeutics and Roivant Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dermata Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Roivant Sciences | 0 | 1 | 9 | 0 | 2.90 |
Roivant Sciences has a consensus price target of $17.10, indicating a potential upside of 60.26%. Given Roivant Sciences’ higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Dermata Therapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dermata Therapeutics | N/A | N/A | -$7.80 million | ($27.74) | -0.06 |
| Roivant Sciences | $124.79 million | 63.16 | $4.35 billion | $5.06 | 2.11 |
Roivant Sciences has higher revenue and earnings than Dermata Therapeutics. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Dermata Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
Profitability
This table compares Dermata Therapeutics and Roivant Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dermata Therapeutics | N/A | -141.27% | -119.03% |
| Roivant Sciences | 3,484.86% | -25.05% | -20.98% |
Insider and Institutional Ownership
8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 9.4% of Dermata Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Roivant Sciences beats Dermata Therapeutics on 11 of the 12 factors compared between the two stocks.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
